A Multi-center, Randomized, Open-label and Positive Controlled Phase II Clinical Trial to Assess Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C.
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PEGIFN
- 31 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jan 2012 Actual patient number is 211 according to ClinicalTrials.gov.
- 30 Jan 2012 Planned end date changed from 1 Mar 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.